CYTEK BIOSCIENCES, INC. Revenue from Contract with Customer, Excluding Assessed Tax
CYTEK BIOSCIENCES, INC. (CTKB) reported Revenue from Contract with Customer, Excluding Assessed Tax of $48.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $48.14M, a 5.57% increase year-over-year.
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $44.13M, a 6.46% increase year-over-year.
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $62.14M, a 8.12% increase year-over-year.
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $52.29M, a 1.54% increase year-over-year.
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $201.49M, a 0.52% increase from fiscal 2024.
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $200.45M, a 3.85% increase from fiscal 2023.
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $193.01M, a 17.67% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $164.04M, a 28.20% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.14M 10-Q · filed 2026-08-05 | $92.28M 10-Q · filed 2026-08-05 | $154.42M derived: sum of 3 quarters · filed 2026-08-05 | $206.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $44.13M 10-Q · filed 2026-05-07 | $106.28M derived: sum of 2 quarters · filed 2026-05-07 | $158.57M derived: sum of 3 quarters · filed 2026-05-07 | $204.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $62.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $114.43M derived: sum of 2 quarters · filed 2026-02-26 | $160.04M derived: sum of 3 quarters · filed 2026-08-05 | $201.49M 10-K · filed 2026-02-26 |
| 2025-09-30 | $52.29M 10-Q · filed 2025-11-05 | $97.89M derived: sum of 2 quarters · filed 2026-08-05 | $139.35M 10-Q · filed 2025-11-05 | $196.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $45.60M 10-Q · filed 2026-08-05 | $87.06M 10-Q · filed 2026-08-05 | $144.53M derived: sum of 3 quarters · filed 2026-08-05 | $196.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $41.46M 10-Q · filed 2026-05-07 | $98.93M derived: sum of 2 quarters · filed 2026-05-07 | $150.43M derived: sum of 3 quarters · filed 2026-05-07 | $197.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $57.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $108.98M derived: sum of 2 quarters · filed 2026-02-26 | $155.59M derived: sum of 3 quarters · filed 2026-02-26 | $200.45M 10-K · filed 2026-02-26 |
| 2024-09-30 | $51.50M 10-Q · filed 2025-11-05 | $98.12M derived: sum of 2 quarters · filed 2025-11-05 | $142.98M 10-Q · filed 2025-11-05 | $201.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $46.62M 10-Q · filed 2025-08-06 | $91.48M 10-Q · filed 2025-08-06 | $149.71M derived: sum of 3 quarters · filed 2026-02-26 | $197.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $44.86M 10-Q · filed 2025-05-08 | $103.09M derived: sum of 2 quarters · filed 2026-02-26 | $151.09M derived: sum of 3 quarters · filed 2026-02-26 | $200.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $58.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $106.23M derived: sum of 2 quarters · filed 2026-02-26 | $155.93M derived: sum of 3 quarters · filed 2026-02-26 | $193.01M 10-K · filed 2026-02-26 |
| 2023-09-30 | $48.00M 10-Q · filed 2024-11-07 | $97.69M derived: sum of 2 quarters · filed 2024-11-07 | $134.78M 10-Q · filed 2024-11-07 | $183.12M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $49.69M 10-Q · filed 2024-08-06 | $86.78M 10-Q · filed 2024-08-06 | $135.12M derived: sum of 3 quarters · filed 2025-02-28 | $175.59M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $37.09M 10-Q · filed 2024-05-08 | $85.42M derived: sum of 2 quarters · filed 2025-02-28 | $125.90M derived: sum of 3 quarters · filed 2025-02-28 | $166.06M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $48.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $88.81M derived: sum of 2 quarters · filed 2025-02-28 | $128.97M derived: sum of 3 quarters · filed 2025-02-28 | $164.04M 10-K · filed 2025-02-28 |
| 2022-09-30 | $40.48M 10-Q · filed 2023-11-14 | $80.64M derived: sum of 2 quarters · filed 2023-11-14 | $115.70M 10-Q · filed 2023-11-14 | $154.59M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $40.16M 10-Q · filed 2023-08-08 | $75.22M 10-Q · filed 2023-08-08 | $114.12M derived: sum of 3 quarters · filed 2024-03-13 | $148.49M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $35.06M 10-Q · filed 2023-05-09 | $73.96M derived: sum of 2 quarters · filed 2024-03-13 | $108.33M derived: sum of 3 quarters · filed 2024-03-13 | $138.74M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $38.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $73.27M derived: sum of 2 quarters · filed 2024-03-13 | $103.68M derived: sum of 3 quarters · filed 2024-03-13 | $127.95M 10-K · filed 2024-03-13 |
| 2021-09-30 | $34.38M 10-Q · filed 2022-11-09 | $64.78M derived: sum of 2 quarters · filed 2022-11-09 | $89.06M 10-Q · filed 2022-11-09 | $119.67M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $30.41M 10-Q · filed 2022-08-10 | $54.68M 10-Q · filed 2022-08-10 | $85.30M derived: sum of 3 quarters · filed 2023-03-01 | $110.39M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $24.27M 10-Q · filed 2022-05-12 | $54.89M derived: sum of 2 quarters · filed 2023-03-01 | $79.99M derived: sum of 3 quarters · filed 2023-03-01 | $99.12M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $30.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $55.72M derived: sum of 2 quarters · filed 2023-03-01 | $74.85M derived: sum of 3 quarters · filed 2023-03-01 | $92.84M 10-K · filed 2023-03-01 |
| 2020-09-30 | $25.10M 10-Q · filed 2021-11-12 | $44.23M derived: sum of 2 quarters · filed 2021-11-12 | $62.22M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $19.14M 10-Q · filed 2021-09-03 | $37.12M 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |